Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Quantitative Analysis of Oncometabolite 2-Hydroxyglutarate.

Advances in experimental medicine and biology - 1 Jan 2021

Yuan Bi-Feng

Abstract excerpt

Gain-of-function mutations of isocitrate dehydrogenase 1 and 2 (IDH1/2) were demonstrated to induce the production and accumulation of oncometabolite 2-hydroxyglutarate (2HG). 2HG is a potent competitor of α-ketoglutarate (α-KG) and can inhibit multiple α-KG-dependent dioxygenases that are critical for regulating the metabolic and epigenetic state of cells. The accumulation of 2HG contributes to elevated risk of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutation
Share to Neoplasms
Share to Glutarates

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Isocitrate Dehydrogenase

Source

Identifiers

PMID: 33791981
DOI: 10.1007/978-3-030-51652-9_11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Quantitative Analysis of Oncometabolite 2-Hydroxyglutarate.PMID 33791981Read ↗

Both Enantiomers of 2-Hydroxyglutarate Modulate the Metabolism of Cultured Human Neuroblastoma CellsSemantic proximity Read ↗

Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate.Semantic proximity Read ↗

2-hydroxyglutarate rides the cancer-immunity cycle.Semantic proximity Read ↗

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectivesSemantic proximity Read ↗

Quantitative analysis of 2-hydroxyglutarate as a controversial oncometabolite in malignant gliomas.Semantic proximity Read ↗

Discovery of chirally dependent protein modifications by D- and L-2-hydroxyglutarates.Semantic proximity Read ↗

Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates.Semantic proximity Read ↗

The Emerging Role of D-2-Hydroxyglutarate as an Oncometabolite in Hematolymphoid and Central Nervous System NeoplasmsSemantic proximity Read ↗

Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.Semantic proximity Read ↗

Hypoxia-driven oncometabolite L-2HG maintains “stemness”-differentiation balance and facilitates immune suppression in pancreatic cancerSemantic proximity Read ↗

Rapid detection of mutation in isocitrate dehydrogenase 1 and 2 genes using mass spectrometry.Semantic proximity Read ↗

Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.